Legato Capital Management LLC Cuts Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Legato Capital Management LLC cut its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,027 shares of the company’s stock after selling 1,140 shares during the quarter. Legato Capital Management LLC owned 0.06% of Day One Biopharmaceuticals worth $786,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its position in shares of Day One Biopharmaceuticals by 11.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock valued at $271,000 after buying an additional 2,180 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth approximately $31,000. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth approximately $866,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Day One Biopharmaceuticals by 90.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after acquiring an additional 57,601 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Day One Biopharmaceuticals by 2.3% in the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock worth $55,336,000 after acquiring an additional 87,262 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now owns 1,034,015 shares in the company, valued at $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $12.21 on Friday. The stock’s fifty day moving average is $12.50 and its two-hundred day moving average is $13.56. The firm has a market capitalization of $1.23 billion, a P/E ratio of -11.85 and a beta of -1.46. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $18.07.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DAWN. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.